<DOC>
	<DOCNO>NCT00974142</DOCNO>
	<brief_summary>This randomize , double-blinded , placebo-controlled trial oral Cyclosporine A ( CsA ) patient advanced stage chronic obstructive pulmonary disease . The purpose study evaluate safety effectiveness CsA therapy adaptive immune response advance stage Chronic Obstructive Pulmonary Disease ( COPD ) . Subjects 45 80 year age confirm diagnosis advance stage COPD , responsive conventional inhaler therapy , meet study requirement , enrol study . A total 30 subject either sex enrol study .</brief_summary>
	<brief_title>Oral Cyclosporine Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Age 45 80 year A confirm diagnosis advance stage COPD , use current accept diagnostic criterion , include clinical/laboratory finding , pulmonary function test , appropriate history exclude disorder could explain lung disease . The accepted range FEV1 include 25 % ≤FEV1 ≤ 60 % Subjects agree maintain stable medication regimen absence disease flare ECOG performance status 0 , 1 , 2 pCO2 &lt; 45 mm Hg , room air oxyhemoglobin saturation &gt; 85 % A willingness participate portion protocol , include serial bronchoscopy , requisite surveillance , ancillary immunologic study followup visit institution For woman childbearing age , negative pregnancy test , willingness use two method contraception , abstinence An ability willingness provide write informed consent Three , exacerbation low respiratory disease past year require systemic corticosteroid , one exacerbation require hospitalization past 6 month Intubation COPD , cause respiratory failure past year Use immunosuppressive therapy include oral prednisone &gt; 10mg per day aerosolize corticosteroid , anytime within three month prior participation Evidence opportunistic infection/colonization airway , i.e. , nonbacterial Evidence systemic illness include hematologic disorder ( define absolute neutrophil count ( ANC ) &lt; 4000 /mL platelet &lt; 120,000/mL ) , cirrhosis , hepatic insufficiency ( total bilirubin , alkaline phosphatase &gt; 1.5 x normal , SGOT , SGPT &gt; 1.2 x normal value ) , coagulopathy ( INR &gt; 1.4 ) , seizure disorder Evidence renal insufficiency calculate creatinine clearance use Cockcroft Gault 's method &lt; 80 ml/min male &lt; 70 ml/min female , serum creatinine &gt; 1.4 mg/dL . Evidence coronary artery disease history , e.g. , angina history myocardial infarction within past 12 month , unless correct CABG within &lt; 5 year , asymptomatic since Evidence systemic abnormal renal function manifest uncontrolled hypertension ( systolic blood pressure &gt; 160mmHg diastolic blood pressure &gt; 90mmHg ) , hyperkalemia ( serum potassium &gt; 5.0 meq/dl , and/or elevate serum potassium normal range subject 's age ) Pregnancy lactation , inability take contraception 6 month follow treatment Positive HIV , hepatitis B C serology , another active infection Current past history cancer exclude basal squamous cell skin cancer Undiagnosed pulmonary nodule require diagnostic evaluation Weight loss &gt; 10 % usual body weight past 6 month BMI &lt; 18 Known hypersensitivity allergy cyclosporine Concurrent participation clinical trial within prior month Known medical psychological condition ( severe personality disorder mental illness ) would permit subject complete trial sign inform consent Autoimmune disorder disorder suspect systemic immune involvement Active smoking history urinary cotinine &gt; 2 Hypersensitivity midazolam narcotic would allow bronchoscopy sedation Concurrent use drug know interaction cyclosporine</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Oral Immunotherapy</keyword>
	<keyword>Advanced stage</keyword>
</DOC>